Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest

被引:89
作者
Ahamad, A [1 ]
Stevens, CW [1 ]
Smythe, WR [1 ]
Liao, ZX [1 ]
Vaporciyan, AA [1 ]
Rice, D [1 ]
Walsh, G [1 ]
Guerrero, T [1 ]
Chang, J [1 ]
Bell, B [1 ]
Komaki, R [1 ]
Forster, KM [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Sect Thorac Mol Oncol,Dept Thorac & Cardiovasc Su, Houston, TX 77030 USA
关键词
mesothelioma; IMRT; radiotherapy;
D O I
10.1097/00130404-200311000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Malignant pleural mesothelioma often recurs locally in spite of aggressive resection by extrapleural pneumonectomy and conventional radiotherapy. This may be due to failure to recognize the extent of clinical target volume (CTV) or suboptimal dose delivery to a target that abuts the heart, esophagus, liver, lung, kidney, and spinal cord. We report how these geometric/dosimetric constraints were overcome by exploiting intensity-modulated radiotherapy in the first cohort patient. MATERIALS AND METHODS Twenty-eight patients who had undergone extrapleural pneumonectomy were treated with intensity-modulated radiotherapy. The CTV included the surgically violated inner chest wall, insertion of diaphragm, pleural reflections, and deep margin of the incision. CTV delineation was facilitated by intraoperative radio-opaque marking. Motion was assessed. CTV doses were 45-50 Gy with boosts taken to 60 Gy. RESULTS Despite the large, irregular CTV (median, 4151 cc; range, 2667-7286 cc), an average of 97% of the CTV was covered to the target dose (range, 92%-100%). Respiratory motion was minimal because of immobility of the prosthetic diaphragm. Normal tissue dose constraints were met. The commonest effects were nausea/vomiting (89%) and dyspnea (80%). Esophagitis. was absent (59% of patients) or mild (34% grade 1/2). At median follow-up of 9 months (range, 5-27 months), local control within the contoured target was 100%. One-year survival, disease-specific survival, and disease-free survival are 65%, 91%, and 88%, respectively. CONCLUSIONS Intensity-modulated radiotherapy after extrapleural pneumonectomy is tolerable and seems effective, at least at this early point. As local control improves, systemic metastases become more common, and it may be appropriate to add novel agents to further improve the therapeutic ratio.
引用
收藏
页码:476 / 484
页数:9
相关论文
共 37 条
  • [1] ANTMAN KH, 1985, CLIN CHEST MED, V6, P127
  • [2] Arbuck SG., The revised common toxicity criteria: Version 2.0
  • [3] Baldini EH, 1997, ANN THORAC SURG, V63, P334
  • [4] THE TREATMENT OF MALIGNANT MESOTHELIOMA OF THE PLEURA - REVIEW OF A 5-YEAR EXPERIENCE, WITH SPECIAL REFERENCE TO RADIOTHERAPY
    BALL, DL
    CRUICKSHANK, DG
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (01): : 4 - 9
  • [5] Bianchi C, 1997, EUR J CANCER PREV, V6, P162
  • [6] Intensity-modulated radiotherapy: Current status and issues of interest
    Boyer, AL
    Butler, EB
    DiPetrillo, TA
    Engler, MJ
    Fraass, B
    Grant, W
    Ling, CC
    Low, DA
    Mackie, TR
    Mohan, R
    Purdy, JA
    Roach, M
    Rosenman, JG
    Verhey, LJ
    Wong, JW
    Cumberlin, RL
    Stone, H
    Palta, JR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (04): : 880 - 914
  • [7] COMPUTERIZED-TOMOGRAPHY SCANNING AND THE PLANNING OF HIGH-DOSE RADIOTHERAPY FOR PLEURAL MESOTHELIOMA - A REPORT OF 5 PATIENTS
    BRICOUT, PB
    ENGLER, MJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (06): : 821 - 826
  • [8] PLEUROPNEUMONECTOMY IN MANAGEMENT OF DIFFUSE MALIGNANT MESOTHELIOMA OF PLEURA - EXPERIENCE WITH 29 PATIENTS
    BUTCHART, EG
    ASHCROFT, T
    BARNSLEY, WC
    HOLDEN, MP
    [J]. THORAX, 1976, 31 (01) : 15 - 24
  • [9] MALIGNANT MESOTHELIOMA OF THE PLEURA - A PROSPECTIVE THERAPEUTIC STUDY OF 132 PATIENTS FROM 1981-1985
    CALAVREZOS, A
    KOSCHEL, G
    HUSSELMANN, H
    TAYLESSANI, A
    HEILMANN, HP
    FABEL, H
    SCHMOLL, HJ
    DIETRICH, H
    HAIN, E
    [J]. KLINISCHE WOCHENSCHRIFT, 1988, 66 (14): : 607 - 613
  • [10] Simian virus 40, poliovaccines and human tumors: a review of recent developments
    Carbone, M
    Rizzo, P
    Pass, HI
    [J]. ONCOGENE, 1997, 15 (16) : 1877 - 1888